Cambridge Trust Co. Grows Stake in Eli Lilly and Company (NYSE:LLY)

Cambridge Trust Co. increased its stake in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,930 shares of the company’s stock after acquiring an additional 78 shares during the period. Cambridge Trust Co.’s holdings in Eli Lilly and Company were worth $6,371,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LLY. Norges Bank purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $3,416,206,000. International Assets Investment Management LLC boosted its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the period. Moneta Group Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after buying an additional 5,440,731 shares during the period. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after buying an additional 3,691,436 shares during the period. Finally, Imprint Wealth LLC boosted its position in shares of Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after buying an additional 1,747,946 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 0.8 %

Shares of LLY stock traded down $6.32 during trading hours on Thursday, reaching $744.45. 990,506 shares of the company’s stock were exchanged, compared to its average volume of 3,057,192. The stock’s 50 day moving average is $764.03 and its 200-day moving average is $657.67. The company has a market cap of $707.35 billion, a price-to-earnings ratio of 129.32, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.09 earnings per share. Analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.